ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0077

Rheumatoid Arthritis – Are We Getting to Target?

myint Thway1, Gurjit S. Kaeley2, Karishma Ramsubeik3, Laurie Ramrattan1, Lilian Otalora Rojas4 and Sukhraj Singh1, 1University of Florida-Jacksonville, Jacksonville, FL, 2UF COM-J, Ponte Vedra Beach, FL, 3University of Florida, Jacksonville, FL, 4University of Florida, Ponte Vedra Beach, FL

Meeting: ACR Convergence 2022

Keywords: Outcome measures, rheumatoid arthritis, Systems-based Studies

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Low disease activity (LDA) is a key goal in treating Rheumatoid arthritis, but implementing the treat to target approach in clinical practice has been suboptimal (1). It would be desirable to survey disease activity status at the practice level. Traditionally, disease activity calculations are embedded in visit documentation, challenging data extraction and aggregation. The automated capture and storage of metrics to calculate major disease indices can generate practice population metrics. Barriers to treatment in high disease activity subjects can be specifically identified and targeted. This abstract reports on the process of implementing standardized metrics capture and reporting on a practice level.

Methods: Using the EPIC software system, the division of rheumatology adopted automated metrics capture of patient and provider global, swollen and tender joint counts, and acute phase reactants to calculate the clinical disease activity index (CDAI), disease activity score-28 ESR (DAS28-ESR), and DAS28-CRP. After one year, provider reports were concatenated, cleaned, extracted, and analyzed using the R-Studio software package. The CDAI metrics stratified subjects into high disease activity (HDA), moderate disease activity (MDA), and (LDA) or remission. A retrospective chart review evaluated factors contributing to high disease activity.

Results: Combining individual provider reports resulted in 3060 records. Elimination of duplicate cases, non-divisional providers, and non-rheumatoid arthritis patients resulted in 214 unique cases. CDAI was the most available metric, followed by DAS28-ESR. The mean age was 60.3 years, with no age differences across the disease strata. Of the population, 85% were female, 69% LDA, 17% MDA, 14% HDA. Fellows and a newer provider tended to see more severe subjects. (Fig 1). DAS28-ESR (197 records) classified more patients as MDA than CDAI. ( 31% vs.17% respectively). CDAI and DAS28-ESR had a good to excellent positive linear correlation (Figure 2) and agreement. (Weighted Kappa = 0.768). Subjects with high disease activity had several barriers to care. (Table 1). The most common reason was restricted access to modern disease modifying agents.

Conclusion: Automated capture and storage of disease activity metrics may enable snapshots of the disease activity of rheumatoid arthritis patients in clinical practice. High disease individuals can be identified for escalated interventions to overcome barriers to attaining control. The report of disease activity measures allows comparison across providers, including trainees, providing valuable insights into the acuity of subjects seen by individuals. The overall concordance of CDAI and DAS28-ESR is reassuring for making treatment decisions at the time of the office visit based on clinical metrics without waiting for the acute phase reactant results. Further enhancements would be to track individual subjects over time and automate the data handling to produce real-time practice dashboards.

References
1. Solomon DH, Losina E, et al. Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial. Arthritis & Rheumatology 2017;69:1374–1380.

Supporting image 1

Figure .1 CADI disease activity by the provider

Supporting image 2

Figure. 2 Relationship between CDAI and DAS28-ESR ( 197 records)

Supporting image 3

Table.1 Results of chart Review of subjects with High disease activity ( HDA) showing reasons of HDA


Disclosures: m. Thway, None; G. Kaeley, None; K. Ramsubeik, None; L. Ramrattan, None; L. Otalora Rojas, None; S. Singh, None.

To cite this abstract in AMA style:

Thway m, Kaeley G, Ramsubeik K, Ramrattan L, Otalora Rojas L, Singh S. Rheumatoid Arthritis – Are We Getting to Target? [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/rheumatoid-arthritis-are-we-getting-to-target/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-are-we-getting-to-target/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology